Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28122937 | 0.71 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL10881206 | 0.71 | DRD3 (0.43) | DRD3 | |
| SCHEMBL24643164 | 0.71 | DRD3 (0.47) | DRD3 | |
| SCHEMBL3660355 | 0.71 | DRD3 (0.41) | DRD3 | |
| SCHEMBL14824203 | 0.69 | HRH3 (0.40) | DRD3 | |
| SCHEMBL10387758 | 0.68 | MEN1 (0.30) | — | |
| SCHEMBL1352840 | 0.66 | — | — | |
| SCHEMBL871135 | 0.66 | — | — | |
| SCHEMBL6712596 | 0.65 | GLA (0.37) | — | |
| SCHEMBL4934409 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104725270-B | Method for preparing butylphenylacetonitrile | 江西吉翔医药化工有限公司 | 2017-01-18 | — | — | CN | claimed |
| CN-104725270-A | Method for preparing butylphenylacetonitrile | JIANGXI JIXIANG PHARMACEUTICAL CO LTD | 2015-06-24 | — | — | CN | claimed |
| CN-104725270-B | Method for preparing butylphenylacetonitrile | 江西吉翔医药化工有限公司 | 2017-01-18 | — | — | CN | disclosed |
| CN-104725270-A | Method for preparing butylphenylacetonitrile | JIANGXI JIXIANG PHARMACEUTICAL CO LTD | 2015-06-24 | — | — | CN | disclosed |
| EP-1569915-A4 | SPIROCYCLIC UREAS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060116366-A1 | Spirocyclic ureas, compositions containing such compounds and methods of use | MERCK & CO., INC. | 2006-06-01 | — | — | US | disclosed |
| EP-1569915-A2 | SPIROCYCLIC UREAS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050039-A2 | SPIROCYCLIC UREAS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116366-A1 | Spirocyclic ureas, compositions containing such compounds and methods of use | UTS2R, GLP1R, GCGR | DRD3 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.